Matthew J. Loza

5.1k total citations
69 papers, 1.9k citations indexed

About

Matthew J. Loza is a scholar working on Immunology, Physiology and Oncology. According to data from OpenAlex, Matthew J. Loza has authored 69 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Immunology, 22 papers in Physiology and 15 papers in Oncology. Recurrent topics in Matthew J. Loza's work include Immune Cell Function and Interaction (23 papers), Asthma and respiratory diseases (20 papers) and T-cell and B-cell Immunology (18 papers). Matthew J. Loza is often cited by papers focused on Immune Cell Function and Interaction (23 papers), Asthma and respiratory diseases (20 papers) and T-cell and B-cell Immunology (18 papers). Matthew J. Loza collaborates with scholars based in United States, United Kingdom and Belgium. Matthew J. Loza's co-authors include B Perussia, Leonid S. Metelitsa, Stephen P. Peters, Mitchell Kronenberg, Robert C. Seeger, Hongwei Wu, Olga V. Naidenko, Anita Kant, Ratko Djukanović and Peter J. Sterk and has published in prestigious journals such as Blood, Nature Immunology and The Journal of Immunology.

In The Last Decade

Matthew J. Loza

63 papers receiving 1.9k citations

Peers

Countries citing papers authored by Matthew J. Loza

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Loza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Loza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Loza more than expected).

Fields of papers citing papers by Matthew J. Loza

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Loza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Loza. The network helps show where Matthew J. Loza may publish in the future.

Co-authorship network of co-authors of Matthew J. Loza

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Loza. A scholar is included among the top collaborators of Matthew J. Loza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Loza. Matthew J. Loza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC 2024 ·JTO Clinical and Research Reports ·Jacqueline V. Aredo, Heather A. Wakelee, Kavitha Ramchandran, Joel W. Neal, Maximilian Diehn, Angela B. Hui, Ameen A. Salahudeen, Bernice Y. Kwong, Gerald J. Berry, H. Henry Guo, Kristen Cunanan, Shireen Vali, (unknown), Vivian W. L. Tsang, (unknown), Matthew J. Loza, Brittany Johnson, (unknown), Sukhmani K. Padda	1
2	Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab 2024 ·Scientific Reports ·Kim Thys, Matthew J. Loza, (unknown), Katleen Callewaert, (unknown), Marjolein Crabbe, Liesbeth Van Wesenbeeck, (unknown), Sandra De Meyer, Jeroen Aerssens, (unknown)	0
3	Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study 2024 ·RMD Open ·Peter C. Taylor, Georg Schett, T. Huizinga, Qingmin Wang, Fowzia Ibrahim, Bei Zhou, (unknown), Jafar Sadik Shaik, Yuan Xiong, Jocelyn H. Leu, Rohit A. Panchakshari, Matthew J. Loza, (unknown), (unknown), (unknown), Chetan S. Karyekar, Carolyn A. Cuff, Sheng Gao, Kaiyin Fei	10
4	Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study 2023 ·ERJ Open Research ·Lydia Finney, (unknown), Dexter Wiseman, Anthony Rowe, Matthew J. Loza, Patrick Branigan, Christopher S. Stevenson, Frédéric Baribaud, Jadwiga A. Wedzicha, Ioannis Pandis, Gavin C. Donaldson	1
5	Serologic Biomarkers of Progression Toward Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel 2022 ·Arthritis & Rheumatology ·Matthew J. Loza, Sunil Nagpal, Suzanne Cole, Renée M. Laird, (unknown), Navin Rao, Mark S. Riddle, Chad K. Porter	4
6	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials 2021 ·RMD Open ·Kristen Sweet, Qingxuan Song, Matthew J. Loza, Iain B. McInnes, Keying Ma, Karen Leander, Vani Lakshminarayanan, (unknown), Philip Cooper, Stefan Siebert	32
7	Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics 2020 ·Contemporary Clinical Trials Communications ·Chad K. Porter, Mark S. Riddle, Renée M. Laird, Matthew J. Loza, Suzanne Cole, (unknown), (unknown), Ramiro L. Gutiérrez, Frédéric Baribaud, Navin Rao, Sunil Nagpal	7
8	Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice 2019 ·The Journal of Immunology ·Fang Shen, Akash Verma, (unknown), Brian H. Jones, Bianca M. Coleman, Matthew J. Loza, Ravi Malaviya, Beverley A. Moore, Daniel Weinstock, M. Merle Elloso, Sarah L. Gaffen, Tatiana Ort	24
9	I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment 2019 ·PLoS Computational Biology ·Stelios Pavlidis, Calixte S. Monast, Matthew J. Loza, Patrick Branigan, (unknown), Ian M. Adcock, Yike Guo, Anthony Rowe, Frédéric Baribaud	16
10	Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials 2019 ·Arthritis & Rheumatology ·Stefan Siebert, Kristen Sweet, B. Dasgupta, Kim Campbell, Iain B. McInnes, Matthew J. Loza	15
11	The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis 2019 ·PLoS ONE ·Carl L. Manthey, Beverley A. Moore, Yanqing Chen, Matthew J. Loza, Xiang Yao, Hao Liu, Stanley M. Belkowski, (unknown), Paul J. Dunford, Francisco León, Jennifer E. Towne, Scott E. Plevy	18
12	A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma 2018 ·Annals of Allergy Asthma & Immunology ·Alexa P. Kollmeier, Elliot S. Barnathan, Christopher O’Brien, Bin Chen, Yichuan Xia, Bei Zhou, Matthew J. Loza, Philip E. Silkoff, (unknown), Robin L. Thurmond	16
13	Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies 2016 ·Annals of the American Thoracic Society ·Matthew J. Loza, Ian M. Adcock, Charles Auffray, (unknown), Ratko Djukanović, Peter J. Sterk, Vedrana S. Susulic, Elliot S. Barnathan, (unknown), Philip E. Silkoff	21
14	Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study 2016 ·Respiratory Research ·(unknown), Philip E. Silkoff, Michel Laviolette, Dileep Kumar Singh, J. Mark FitzGerald, Steven Kelsen, Vibeke Backer, Celeste Porsbjerg, Pierre‐Olivier Girodet, Patrick Berger, Joel N. Kline, Sumita Khatri, Pascal Chanez, Vedrana S. Susulic, Elliot S. Barnathan, Fred Baribaud, Matthew J. Loza	29
15	β-Agonist enhances type 2 T-cell survival and accumulation 2006 ·Journal of Allergy and Clinical Immunology ·Matthew J. Loza, Stephen P. Peters, Susan Leigh Foster, Islam Ullah Khan, (unknown)	27
16	The IL-12 Signature: NK Cell Terminal CD56+high Stage and Effector Functions 2004 ·The Journal of Immunology ·Matthew J. Loza, B Perussia	89
17	Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell 2004 ·Molecular Immunology ·B Perussia, (unknown), Matthew J. Loza	38
18	Peripheral Immature CD2−/low T Cell Development from Type 2 to Type 1 Cytokine Production 2002 ·The Journal of Immunology ·Matthew J. Loza, B Perussia	18
19	Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells 2001 ·The Journal of Immunology ·Leonid S. Metelitsa, Olga V. Naidenko, Anita Kant, Hongwei Wu, Matthew J. Loza, B Perussia, Mitchell Kronenberg, Robert C. Seeger	293
20	B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells 2001 ·The Journal of Immunology ·(unknown), Rossana Trotta, Matthew J. Loza, (unknown), Renato V. Iozzo, (unknown), B Perussia, Bruno Calabretta	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact